Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Free Cash Flow (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Free Cash Flow for 9 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 795.14% to $31.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.7 million, a 266.37% increase, with the full-year FY2025 number at $67.7 million, up 266.37% from a year prior.
  • Free Cash Flow was $31.1 million for Q4 2025 at Akebia Therapeutics, up from $28.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $33.8 million in Q3 2022 to a low of -$70.8 million in Q1 2021.
  • A 5-year average of -$16.1 million and a median of -$11.8 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 378.18% in 2024, then surged 795.14% in 2025.
  • Akebia Therapeutics' Free Cash Flow stood at -$62.8 million in 2021, then grew by 12.94% to -$54.7 million in 2022, then soared by 95.78% to -$2.3 million in 2023, then crashed by 93.59% to -$4.5 million in 2024, then soared by 795.14% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Free Cash Flow are $31.1 million (Q4 2025), $28.0 million (Q3 2025), and $22.2 million (Q2 2025).